Concepedia

Institution (Company)

Moderna Therapeutics (United States)

HomepageROR

Also Known As

Moderna Therapeutics (United States)

1.3K

Publications

284K

Citations

247

Authors

250

Concepts

About

Moderna Therapeutics (United States) is a company institution in Cambridge, United States known for medicine, immunology, and vaccination.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

56

692

93.2K

2

Engineering

15

58

7.1K

3

Natural Sciences

9

57

14.7K

4

Public Health

7

9

466

5

Health Sciences

4

31

2K

Moderna Therapeutics (United States)

×

1.3K

Publications

284K

Citations

YearCitations

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Kizzmekia S. Corbett, Darin K. Edwards, Sarah R. Leist,

Nature

2020

1.6K

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Evan J. Anderson, Nadine Rouphael, Alicia T. Widge,

New England Journal of Medicine

2020

1.6K

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Peter B. Gilbert, David C. Montefiori, Adrian B. McDermott,

Science

2022

1.2K

Pharmaceutical cocrystals: along the path to improved medicines

Naga Kiran Duggirala, Miranda L. Perry, Örn Almarsson,

Chemical Communications

2015

900

Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines

Kimberly J. Hassett, Kerry E. Benenato, Eric Jacquinet,

Molecular Therapy — Nucleic Acids

2019

841

A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates

Staci Sabnis, E. Sathyajith Kumarasinghe, Timothy Salerno,

Molecular Therapy

2018

753

Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses

Kapil Bahl, Joe J. Senn, Olga Yuzhakov,

Molecular Therapy

2017

646

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

Spyros Chalkias, Charles Harper, Keith Vrbicky,

New England Journal of Medicine

2022

638

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak,

The Lancet

2024

598

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

Hung Fu Tseng, Bradley K. Ackerson, Yi Luo,

Nature Medicine

2022

544

Page 1